Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia： Specificity and Sensitivity in Clinical Practice

NCT06533410 · tracked via the Priya Life Science China tracker

Sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Phase

—

Started

2024-05-21

Last updated

2024-10-21

Condition(s) studied

Fibromyalgia

Investigational drug(s) / intervention(s)

The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that

The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that: The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that

Study summary

This study aimed to evaluate the specificity and sensitivity of the diagnostic criteria for fibromyalgia after conducting local validation in China.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * At least 18 years of age; Patients with chronic widespread pain; Able to complete the questionnaire. Exclusion Criteria: * Terminal patients with severe psychiatric diseases, tumors, systemic lupus erythematosus, systemic sclerosis, or other serious diseases.

Primary outcome measure(s)

Diagnosis of fibromyalgia with the Polysymptomatic Distress Scale(PDS) — up to 1 week
The PDS scale fibromyalgia severity (FS) scale also known as the fibromyalgia severity (FS) scale. It is the sum of the WPI and SSS, and ranges is from 0-31 with higher score indicating more severity.

Trial sites (1)

Facility	City	Region	Status
Guang'anmen Hospital	Beijing	Beijing Municipality	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06533410 on ClinicalTrials.gov ↗ ← All trials in China